Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Participant demographics

From: Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin

Measure

ASD (n = 13)

Neurotypicals (n = 15)

Test statistic

Age at visit 1 (years)

30.6 ± 11.2 [20–50]

28.5 ± 6.1 [21–40]

F(1, 26) = 0.389, p = .538

ADI coma

7.5 ± 5.0

  

ADI repa

4.0 ± 2.6

  

ADOS com

4.4 ± 3.3

  

ADOS soc

7.6 ± 4.1

  

AQa

29.1 ± 13.7

  

FSIQ

113.0 ± 18.1

125.3 ± 12.7

F(1, 26) = 4.421, p = .045

TV1–V2 (days)

31.2 ± 17.9

28.1 ± 15.0

F(1, 26) = 0.248, p = .623

Mean motion (CBDV)

0.015 ± 0.067

0.008 ± 0.043

F(1, 26) = 0.100, p = .754

Mean motion (PLC)

0.014 ± 0.049

0.008 ± 0.050

F(1, 26) = 0.097, p = .758

  1. Demographics (mean ± standard deviation [range])) and test statistic of between-group comparison
  2. ADI autism diagnostic interview (com, communication domain; rep, restricted and repetitive behaviours domain), ADOS autism diagnostic observation schedule (com, communication domain; soc, social domain), AQ autism quotient, CBDV cannabidivarin, FSIQ full-scale intelligence quotient, PLC placebo, TV1–V2, time between visits 1 and 2
  3. an = 10
Back to article page

Molecular Autism

ISSN: 2040-2392